DiaMedica Therapeutics Inc (NASDAQ: DMAC) on Friday, soared 5.68% from the previous trading day, before settling in for the closing price of $7.22. Within the past 52 weeks, DMAC’s price has moved between $3.19 and $7.68.
Healthcare Sector giant saw their annual sales surged by 7.39% over the last five years. The company achieved an average annual earnings per share of -14.00%. With a float of $24.57 million, this company’s outstanding shares have now reached $52.08 million.
DiaMedica Therapeutics Inc (DMAC) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of DiaMedica Therapeutics Inc is 52.82%, while institutional ownership is 24.90%. The most recent insider transaction that took place on Aug 25 ’25, was worth 2,029,252. In this transaction 10% Owner of this company bought 338,265 shares at a rate of $6.00, taking the stock ownership to the 7,654,045 shares. Before that another transaction happened on Aug 13 ’25, when Company’s 10% Owner bought 293,601 for $5.91, making the entire transaction worth $1,734,918. This insider now owns 7,058,066 shares in total.
DiaMedica Therapeutics Inc (DMAC) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.18 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.17) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -13.62% during the next five years compared to 7.39% growth over the previous five years of trading.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) Trading Performance Indicators
DiaMedica Therapeutics Inc (DMAC) is currently performing well based on its current performance indicators. A quick ratio of 10.67 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.72, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of DiaMedica Therapeutics Inc (DMAC)
Analysing the last 5-days average volume posted by the [DiaMedica Therapeutics Inc, DMAC], we can find that recorded value of 0.76 million was better than the volume posted last year of 0.24 million. As of the previous 9 days, the stock’s Stochastic %D was 91.72%.
During the past 100 days, DiaMedica Therapeutics Inc’s (DMAC) raw stochastic average was set at 98.79%, which indicates a significant increase from 97.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.55 in the past 14 days, which was higher than the 0.39 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.77, while its 200-day Moving Average is $5.25. Now, the first resistance to watch is $7.85. This is followed by the second major resistance level at $8.08. The third major resistance level sits at $8.47. If the price goes on to break the first support level at $7.23, it is likely to go to the next support level at $6.84. Now, if the price goes above the second support level, the third support stands at $6.61.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) Key Stats
Market capitalization of the company is 397.35 million based on 52,077K outstanding shares. Right now, sales total 0 K and income totals -24,440 K. The company made 0 K in profit during its latest quarter, and -8,620 K in sales during its previous quarter.
